Another multicenter retrospective study reported an ORR of 0%, mPFS of 2.5 months (95% CI: 1.5–3.7), and mOS of 17.0 months (95% CI: 3.6–NR) for 23 NSCLC patients with ALK-rearrangement treated with IO monotherapy [54]. Here, ALK is linked to non-small cell lung carcinoma.